rosuvastatin
E852341
Rosuvastatin is a statin medication used to lower cholesterol and reduce cardiovascular risk by inhibiting HMG-CoA reductase.
Statements (57)
| Predicate | Object |
|---|---|
| instanceOf |
HMG-CoA reductase inhibitor
ⓘ
lipid-lowering drug ⓘ prescription drug ⓘ small molecule ⓘ statin ⓘ |
| approvedBy | U.S. Food and Drug Administration NERFINISHED ⓘ |
| approvedIn | 2003 ⓘ |
| belongsToChemicalClass | pyrimidine-derived statin ⓘ |
| commonAdverseEffect |
abdominal pain
ⓘ
headache ⓘ myalgia ⓘ |
| contraindication |
active liver disease
ⓘ
breastfeeding ⓘ pregnancy ⓘ severe renal impairment without dose adjustment ⓘ |
| developedBy | AstraZeneca NERFINISHED ⓘ |
| hasATCCode | C10AA07 ⓘ |
| hasBlackBoxWarning | fetal toxicity risk in pregnancy ⓘ |
| hasBrandName |
Crestor
NERFINISHED
ⓘ
Rosulip NERFINISHED ⓘ Rosuva NERFINISHED ⓘ |
| hasCASNumber | 287714-41-4 ⓘ |
| hasChirality | contains chiral centers ⓘ |
| hasEliminationHalfLife | approximately 19 hours ⓘ |
| hasGenericName | rosuvastatin ⓘ |
| hasINN | rosuvastatin ⓘ |
| hasLegalStatus | prescription only ⓘ |
| hasMolecularFormula | C22H28FN3O6S ⓘ |
| hasPharmacologicalClass |
antihyperlipidemic agent
ⓘ
cardiovascular system agent ⓘ |
| hasPregnancyCategory | contraindicated ⓘ |
| hasRouteOfAdministration | oral ⓘ |
| increasesBiomarker | high-density lipoprotein cholesterol ⓘ |
| isAdministeredAs | oral tablet ⓘ |
| isMetabolizedBy |
CYP2C19
NERFINISHED
ⓘ
CYP2C9 NERFINISHED ⓘ |
| isSubstrateOf |
BCRP
NERFINISHED
ⓘ
OATP1B1 NERFINISHED ⓘ |
| isUsedInCombinationWith | ezetimibe ⓘ |
| maximumRecommendedDose | 40 mg once daily ⓘ |
| mechanismOfAction |
inhibition of HMG-CoA reductase
ⓘ
reduction of hepatic cholesterol synthesis ⓘ |
| reducesBiomarker |
low-density lipoprotein cholesterol
ⓘ
total cholesterol ⓘ triglycerides ⓘ |
| seriousAdverseEffect |
hepatic dysfunction
ⓘ
myopathy ⓘ rhabdomyolysis ⓘ |
| therapeuticUse |
increase of HDL cholesterol
ⓘ
prevention of cardiovascular events ⓘ reduction of LDL cholesterol ⓘ reduction of triglycerides ⓘ treatment of homozygous familial hypercholesterolemia ⓘ treatment of mixed dyslipidemia ⓘ treatment of primary hypercholesterolemia ⓘ |
| typicalStartingDose |
10 mg once daily
ⓘ
5 mg once daily ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.